Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 5,927 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 116
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, BI1356 low dose, BI1356 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: San Antonio, Texas • Norfolk, Virginia

Conditions: Crohn's Disease
Interventions: PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 57
States / cities: Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more

Conditions: Myelodysplastic Syndromes
Interventions: Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Colorectal Cancer
Interventions: lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Los Angeles, California • Poway, California • Torrington, Connecticut + 46 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: RXDX-106; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Peri-Implantitis
Interventions: Minocycline HCl Microspheres; Drug
Lead sponsor: OraPharma; Industry
Eligibility: 21 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL plus tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 5
States / cities: Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Healthy, no Evidence of Disease, Skin Cancer
Interventions: cholecalciferol; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions: Cladribine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cetuximab, BIBW 2992; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: Aurora, Colorado • New Haven, Connecticut • New York, New York + 1 more

Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions: Oral Topotecan and Temodar; Drug
Lead sponsor: Katy Peters; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Myelofibrosis
Interventions: SAR302503 (TG101348); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: La Jolla, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Shoulder Arthroscopy, Knee Arthroscopy
Interventions: Sugar pill, Gabapentin, Clonidine; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Cisplatin, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Schizophrenia
Interventions: LTX-001 once daily, Placebo, LTX-001 twice daily; Drug
Lead sponsor: Leal Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more

Conditions: Diabetes
Interventions: Boost Glucose Control (A), Boost Glucose Control (B), Boost Original; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 20 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Tustin, California

Conditions: Health Behavior, Quality of Life, Aging
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 110 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Participants
Interventions: Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more

Conditions: Dental Caries
Interventions: Toothpaste & Telephone Support; Behavioral
Lead sponsor: Advantage Dental Services, LLC; Industry
Eligibility: 6 Months to 20 Years
Enrollment: 21,731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Redmond, Oregon

Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions: Deucrictibant, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more

Search by objective public record fields.

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus

The Lake Nona Life Project

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Everybody Brush: A Community-wide Toothpaste Distribution Campaign

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema